Clinical Implications of DNA Repair Defects in High-Grade Serous Ovarian Carcinomas
Despite significant improvements in surgical and medical management, high grade serous ovarian cancer (HGSOC) still represents the deadliest gynecologic malignancy and the fifth most frequent cause of cancer-related mortality in women in the USA. Since DNA repair alterations are regarded as the “the...
Main Authors: | Michela Camilla Milanesio, Silvia Giordano, Giorgio Valabrega |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-05-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/12/5/1315 |
Similar Items
-
Integration of PARP-inhibitors in ovarian cancer therapy
by: Antonella Pietragalla, et al.
Published: (2020-06-01) -
Exploiting the Prevalence of Homologous Recombination Deficiencies in High-Grade Serous Ovarian Cancer
by: Sara Bouberhan, et al.
Published: (2020-05-01) -
Development of a Genomic Signatures-Based Predictor of Initial Platinum-Resistance in Advanced High-Grade Serous Ovarian Cancer Patients
by: Yuan Li, et al.
Published: (2021-03-01) -
Homologous Recombination Repair Mechanisms in Serous Endometrial Cancer
by: Jenny-Maria Jönsson, et al.
Published: (2021-01-01) -
PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies
by: Elizabeth K. Lee, et al.
Published: (2020-07-01)